This webinar will provide attendees with the knowledge and skills needed to develop and produce an OTC drug product for marketing and sale in the U.S.
The Food and Drug Administration and the Consumer Product Safety Commission have regulations pertaining to OTC drugs. The U.S. Food and Drug Administration's (FDA) is responsible for the regulation and oversight of the U.S. OTC drug market. Congress has granted FDA regulatory authority over the formulation, manufacturing, labeling, marketing and promotion; and import / export of OTC drug products into the U.S. Under this current regulatory regime, there are 4 pathways that a company may follow to enter the OTC drug market including (a) following an appropriate Drug Monograph; (b) with an Agency approved New Drug Application (NDA); (c) via the currently popular Rx-to-OTC Switch Process or (d) via an ANDA citing a previously-approved product.
WHY SHOULD YOU ATTEND?
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
AREA COVERED
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
LEARNING OBJECTIVES
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
WHO WILL BENEFIT?
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
Speaker Profile
Dr. Loren Gelber
Dr. Loren Gelber has worked in the pharmaceutical industry for more than 40 years, at both the FDA and in private industry. She has prepared more than 50 submissions to the FDA. Her specialty is compliance with US regulatory requirements. She has a BA in Biology, an MS in Chemistry and a Ph.D. in Medicinal Chemistry.
Upcoming Webinars
AI for Project Managers: Smarter Planning Reporting and Com…
Mastering Performance Management: Strategies for Continuous…
ChatGPT for Innovative Business Advisory Services for Accou…
Female to Female Hostility @Workplace: All you Need to Know
Latest Trends in Human Error Reduction in GMP Manufacturing
Bootcamp for New Managers and Supervisors: Develop These Es…
Analytical Method Validation Under Good Laboratory Practice…
2-Hour Virtual Seminar on The Complexity and Interplay Amon…
2-Hour Virtual Seminar on How to Conduct an Internal Harass…
Data Integrity and Privacy - Compliance with 21 CFR Part 11…
Do's and Don'ts of Documenting Employee Behaviour, Performa…
Fostering a Culture of Respect: Eliminating Gossip, Rumour…
The Perfect Storm Coming to Healthcare: Value Based Care Me…
Payroll Record Keeping: How to Thin Out File Cabinets and Q…
Medical Device Cybersecurity Following FDA’s 2026 Premarket…
Construction Lending And Real Credit Administration: Evalua…
HIPAA Compliance in 2026 — Practical Strategies for Breach …
Moving From an Operational Manager to a Strategic Leader
Launch Your Career: The Ultimate Guide for Emerging Profess…
Dealing With Difficult People: At Work & In Life
I-9 Audits: Strengthening Your Immigration Compliance Strat…
Discover how Emotional Intelligence turns AI from a technic…
The 6 Most Common Problems in FDA Software Validation and V…
High-Impact Performance Management: Tools, Tactics & Coachi…
The 60 Minutes Introduction to DAX
Empowering Conflict Resolution: Letting Go to Gain Control
AI Across the Business: Practical Use Cases for Founders an…
Faster, Better Talent Acquisition: Leveraging AI & ChatGPT …
The Anti-Kickback Statute: Enforcement and Recent Updates
Goal Mastery: From Resolutions to Results in 2026
Your AI Advantage: How HR Professionals Can Use Claude to S…
Human Error Reduction Techniques for Floor Supervisors
Validation of FDA-Regulated Medical Device and SaMD Product…
Human Factors Usability Studies Following ISO 62366 and FDA…